|
Synonyms: B2036-PEG | Somavert®
pegvisomant is an approved drug (FDA (2003), EMA (2008))
Compound class:
Peptide or derivative
Comment: Pegvisomant is a PEGylated 191 amino acid protein analogue of growth hormone, with antagonist action at the growth hormone receptor. The peptide sequence can be obtained via the ChEMBL link. PEGylation protects the peptide from proteolytic breakdown and extends its bioactive half-life.
|
| References |
|
1. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German Pegvisomant Investigators. (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol, 156 (1): 75-82. [PMID:17218728] |
|
2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML et al.. (2000)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med, 342 (16): 1171-7. [PMID:10770982] |
